Central Nervous System News and Research

RSS

Young football players may be at higher risk for stroke

Young football players may be at higher risk for stroke, according to a new study released in Journal of Child Neurology (JCN), published by SAGE.

9 Dec 2011

Intensive maternal care during infancy promotes effect of NPY in brain

Neuropeptide Y (NPY) is the most abundant peptide hormone of the central nervous system. It is involved in various processes including stress management, the development of anxiety behaviour and body weight regulation. A collaborative research group including scientists from the Max Planck Institute for Medical Research in Heidelberg has demonstrated using mice that intensive maternal care during infancy promotes the effect of NPY in the brain.

8 Dec 2011

UCSF resident to receive 2012 William P. Van Wagenen Fellowship

The William P. Van Wagenen Fellowship Selection Committee has announced Matthew Christopher Tate, MD, as the recipient of the 2012 William P. Van Wagenen Fellowship. Dr. Tate, a resident in neurological surgery at University of California in San Francisco, will commence the fellowship on July 1, 2012.

7 Dec 2011

WSU study to improve diagnosis of fetal alcohol spectrum disorders

Fetal alcohol spectrum disorders (FASDs) are one of the most common causes of birth defects worldwide and are particularly prevalent in some South African communities where heavy drinking during pregnancy is a major public health issue, particularly in the wine-growing areas of the Western Cape.

6 Dec 2011

Researchers identify brain area that controls voluntary movement after damage

Researchers have identified the area of the brain that controls our ability to correct our movement after we've been hit or bumped -- a finding that may have implications for understanding why subjects with stroke often have severe difficulties moving.

6 Dec 2011

Study reveals mechanism of action of laquinimod in patients with RRMS

Laquinimod is an orally available synthetic compound that has been successfully evaluated in phase II/III clinical studies for the treatment of relapsing-remitting multiple sclerosis (RRMS).

6 Dec 2011

EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it is presenting the comprehensive analysis of a recently completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia at the American College of Neuropsychopharmacology 50th Anniversary Annual Meeting.

5 Dec 2011

Researchers identify critical steps leading to myelin destruction in neuromyelitis optica

Mayo Clinic researchers have identified critical steps leading to myelin destruction in neuromyelitis optica (NMO), a debilitating neurological disease that is commonly misdiagnosed as multiple sclerosis (MS). The findings could lead to better care for the thousands of patients around the world with NMO. The paper was published in the journal, Proceedings of the National Academy of Sciences, USA.

3 Dec 2011

First study to investigate risk factors for CCSVI in patients without neurological disease

The first study to investigate risk factors for the vascular condition called CCSVI (chronic cerebrospinal venous insufficiency) in volunteers without neurological disease has identified what the researchers call a remarkable similarity between this condition and possible or confirmed risk factors for multiple sclerosis.

1 Dec 2011

World-renowned neurosurgeon to receive Franc D. Ingraham Distinguished Service Award

Children's Hospital Boston today announced that world renowned neurosurgeon R. Michael Scott, MD, will be awarded the prestigious Franc D. Ingraham Distinguished Service Award.

30 Nov 2011

PTC, Roche announce licensing agreement for SMA programme

Roche, PTC Therapeutics, Inc. and the SMA Foundation, announced today a licensing agreement for PTC's Spinal Muscular Atrophy (SMA) programme.

30 Nov 2011

Ferrer introduces citicoline oral solution medical food

Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.

29 Nov 2011

GVK Biosciences and Moulder Center at Temple University enter drug discovery alliance

GVK Biosciences, Asia's leading drug discovery research & development organization, announced today that it has entered into a drug discovery alliance with the Moulder Center for Drug Discovery Research at Temple University.

28 Nov 2011

Moleac launches NurAiD II in France and Belgium

Biopharmaceutical Company Moleac has announced the launch in France and Belgium of NurAiD II. NurAiD II is a natural health supplement engineered to stimulate neuroplasticity and recovery.

25 Nov 2011

Carefully selected young, healthy neurons can repair brain circuitry

Neuron transplants have repaired brain circuitry and substantially normalized function in mice with a brain disorder, an advance indicating that key areas of the mammalian brain are more reparable than was widely believed.

24 Nov 2011

MC3R gene plays an important role in maintaining steady weight

Against the backdrop of the growing epidemic of obesity in the United States, scientists from the Florida campus of The Scripps Research Institute have made an important new discovery regarding a specific gene that plays an important role in keeping a steady balance between our food intake and energy expenditure. The study may help scientists better understand the keys to fighting obesity and related disorders such as diabetes.

24 Nov 2011

Bioengineering delivers innovative solutions to diagnose and repair TBI

Bioengineering -- the application of engineering principles to understand and treat medical conditions -- is delivering innovative solutions for diagnosing and repairing damage to the brain caused by a traumatic injury.

23 Nov 2011

PAREXEL implements fMRI technology in early phase CNS drug development

PAREXEL International, a leading global biopharmaceutical services provider, today announced that it has enhanced its central nervous system (CNS) capabilities for clinical development through the implementation of functional magnetic resonance imaging (fMRI) technology in its Early Phase units.

From Parexel 22 Nov 2011

FDA accepts Otsuka's aripiprazole depot formulation NDA for review

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced today that the U.S. Food and Drug Administration has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia in adults is sufficiently complete to permit a substantive review.

22 Nov 2011

New way to enhance effects of anandamide in the body

UC Irvine and Italian researchers have discovered a new means of enhancing the effects of anandamide - a natural, marijuana-like chemical in the body that provides pain relief.

22 Nov 2011